Related Experiment Video
Updated: Jun 17, 2026
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
What have we learnt from targeted anti-TNF therapy?
M Feldmann1, R O Williams, E Paleolog
1Kennedy Institute of Rheumatology Division, Imperial College, 65 Aspenlea Road, London W6 8LH, UK. m.feldmann@imperial.ac.uk
Annals of the Rheumatic Diseases
|December 10, 2009
Summary
Anti-tumour necrosis factor (anti-TNF) therapy has been used for rheumatoid arthritis since 1992. This review examines anti-TNF knowledge, gaps, and potential cytokine-based treatments for unmet clinical needs.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Anti-tumour necrosis factor (anti-TNF) therapy has been a cornerstone in rheumatoid arthritis (RA) treatment since the early 1990s.
- Extensive research has elucidated the mechanisms by which anti-TNF agents provide therapeutic benefits in RA patients.
Purpose of the Study:
- To review current knowledge and identify existing gaps in understanding anti-TNF therapy for rheumatoid arthritis.
- To explore the role of the TNF-dependent cytokine cascade in RA pathogenesis and treatment.
- To discuss novel therapeutic strategies, including cytokine analysis, for addressing unmet clinical needs in RA.
Main Methods:
- Literature review of studies on anti-TNF therapy in rheumatoid arthritis.
- Analysis of the TNF-dependent cytokine cascade and its implications.
- Exploration of potential new treatment approaches.
Main Results:
- Significant progress has been made in understanding anti-TNF therapy, but knowledge gaps remain.
- The TNF-dependent cytokine cascade plays a crucial role in RA.
- Cytokine analysis may offer new avenues for treating RA and addressing unmet clinical needs.
Conclusions:
- While anti-TNF therapies have advanced RA treatment, further research is needed to address remaining challenges.
- Understanding the cytokine network is key to developing more effective and targeted therapies.
- Cytokine profiling holds promise for personalized medicine and managing refractory RA cases.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...